South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

After a decade of being the primary supplier of human insulin pens in South Africa, Novo decided against bidding for the 2024 ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from REDEFINE 2, a Phase III trial ...

In 2024, Novo Nordisk’s GLP-1 sales in diabetes increased 21%, depicting greater patient outreach and market capture by its GLP-1 products. Novo Nordisk continues to be theglobal marketleader in ...

The "Insulin Pens Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.The report is built to visualize ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...